Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 6/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 1.00 |
| ▸ | MGAM | O43451 | 5/20 | 0.93 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.93 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19745374 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL19557590 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL15593220 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL13317732 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL10028909 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL14268489 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL4319863 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL2435520 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL466573 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL13848041 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102639-A1 | N-ARYLPYRAZOLE NOD2 AGONISTS AS PROMOTERS OF IMMUNE CHECKPOINT INHIBITOR THERAPY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-05-16 | — | — | WO | claimed |
| CN-116920617-A | Preparation method of in-situ immobilized laccase polyvinylidene fluoride membrane | 沈阳建筑大学 | 2023-10-24 | — | — | CN | claimed |
| WO-2023090761-A1 | METHOD FOR ELECTROSPINNING OF HIGH-EFFICIENCY NANOFIBER AIR FILTER BY USING PVDF-G-POEM DOUBLE COMB COPOLYMER | 주식회사 레몬 | 2023-05-25 | — | — | WO | claimed |
| US-20230058412-A1 | Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response | NORTHWESTERN UNIVERSITY | 2023-02-23 | — | — | US | claimed |
| US-20230038373-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2023-02-09 | — | — | US | claimed |
| EP-3976233-A1 | SEQUESTERING COMPOSITIONS AND MATERIALS | Alliance for Sustainable Energy, LLC (US) | 2022-04-06 | — | — | EP | claimed |
| CN-215646221-U | Charge-discharge control circuit based on Type-c interface | 深圳维普创新科技有限公司 | 2022-01-25 | — | — | CN | claimed |
| US-20210402002-A1 | CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-12-30 | — | — | US | claimed |
| US-20210205443-A1 | Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response | NORTHWESTERN UNIVERSITY | 2021-07-08 | — | — | US | claimed |
| WO-2021123506-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-06-24 | — | — | WO | claimed |
| US-20020198225-A1 | Administering a competitive inhibitor of the enzyme in an amount effective to enhance enzyme activtiy, selected from 2,5-dideoxy- 2,5-imino-D-mannitol, 3,4-diepi- alpha -homonojirimycin, 5-O- deoxyglactonojirimycin, calystegines | MOUNT SINAI SCHOOL OF MEDICINE | 2002-12-26 | — | — | US | claimed |
| US-20020156100-A1 | 1-deoxy-galactonojirimycin and related compounds used to treat fabry disease | MOUNT SINAI SCHOOL OF MEDICINE | 2002-10-24 | — | — | US | claimed |
| US-20020035072-A1 | Administering reversible competitive inhibitor of enzyme in an amount effective to enhance activity of enzyme in cell | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY. | 2002-03-21 | — | — | US | claimed |
| US-6274597-B1 | ADMINISTERING 1-DEOXYGALACTONOJIRIMYCIN AND RELATED COMPOUNDS TO TREAT FABRY DISEASE | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2001-08-14 | — | — | US | claimed |
| EP-1083899-A1 | METHOD OF ENHANCING LYSOSOMAL $g(a)-GALACTOSIDASE A | Fan, Jian-Qiang (US) | 2001-03-21 | — | — | EP | claimed |
| WO-1999062517-A1 | METHOD OF ENHANCING LYSOSOMAL α-GALACTOSIDASE A | FAN JIAN QIANG (US) | 1999-12-09 | — | — | WO | claimed |
| EP-0561820-B1 | CONTROL OF PARASITIC NEMATODES | BRITISH TECH GROUP (GB) | 1996-03-20 | — | — | EP | claimed |
| US-5376675-A | Applying 2R,5R-dihydroxymethyl-3R,4R-dihydroxypyrrolidine | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-12-27 | — | — | US | claimed |
| EP-0561820-A1 | CONTROL OF PARASITIC NEMATODES (A). | BRITISH TECH GROUP (GB) | 1993-09-29 | — | — | EP | claimed |
| WO-1992009202-A1 | CONTROL OF PARASITIC NEMATODES (A) | BRITISH TECHNOLOGY GROUP LTD (GB) | 1992-06-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035072-A1 | Administering reversible competitive inhibitor of enzyme in an amount effective to enhance activity of enzyme in cell | GAA, MAN2B1, IDE | GLA 29/4885AGL 25/4885GAA 1/4885 |
| US-20020198225-A1 | Administering a competitive inhibitor of the enzyme in an amount effective to enhance enzyme activtiy, selected from 2,5-dideoxy- 2,5-imino-D-mannitol, 3,4-diepi- alpha -homonojirimycin, 5-O- deoxyglactonojirimycin, calystegines | MAN2B1, GAA, MAN2A1 | GLA 34/4885AGL 31/4885GAA 2/4885 |
| US-20210402002-A1 | CONJUGATE | ST6GAL1, CSGALNACT1, FUT6 | GLA 278/4885AGL 564/4885GAA 72/4885 |
| US-20020156100-A1 | 1-deoxy-galactonojirimycin and related compounds used to treat fabry disease | GAA, GALC, GLA | GLA 3/4885AGL 189/4885GAA 1/4885 |
| US-20230038373-A1 | STABILE CONJUGATE | CD2, TTL, DDOST | GLA 536/4885AGL 308/4885GAA 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.